Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)


Cooper, H.L., Healy, E., Theaker, J.M. and Friedmann, P.S. (2003) Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clinical and Experimental Dermatology, 28, (4), 366-368. (doi:10.1046/j.1365-2230.2003.01283.x).

Download

Full text not available from this repository.

Description/Abstract

We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.

Item Type: Article
ISSNs: 0307-6938 (print)
Related URLs:
Subjects: R Medicine > RL Dermatology
Divisions: University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair
ePrint ID: 27003
Date Deposited: 26 Apr 2006
Last Modified: 27 Mar 2014 18:15
Contact Email Address: P.S.Friedmann@soton.ac.uk
URI: http://eprints.soton.ac.uk/id/eprint/27003

Actions (login required)

View Item View Item